GLS and ovarian carcinoma: Increased expression of glutaminase and the glutamine transporter SLC1A5/ASCT2 has been observed in cisplatin-resistant ovarian cancer cells, and the inhibition of ASCT2 and glutaminase has been shown to sensitize these cells to cisplatin [160].